Your browser doesn't support javascript.
loading
Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri, Aadel A; Binkley, Michael S; Rigdon, Joseph; Carter, Justin N; Aggarwal, Sonya; Dudley, Sara A; Qian, Yushen; Kumar, Kiran A; Hara, Wendy Y; Gensheimer, Michael; Nair, Viswam S; Maxim, Peter G; Shultz, David B; Bush, Karl; Trakul, Nicholas; Le, Quynh-Thu; Diehn, Maximilian; Loo, Billy W; Guo, Haiwei Henry.
Afiliación
  • Chaudhuri AA; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Binkley MS; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Rigdon J; Quantitative Sciences Unit, Stanford University School of Medicine, United States.
  • Carter JN; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Aggarwal S; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Dudley SA; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Qian Y; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Kumar KA; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Hara WY; Department of Radiation Oncology, Stanford University School of Medicine, United States; Stanford Cancer Institute, Stanford University School of Medicine, United States.
  • Gensheimer M; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Nair VS; Department of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, United States.
  • Maxim PG; Department of Radiation Oncology, Stanford University School of Medicine, United States; Stanford Cancer Institute, Stanford University School of Medicine, United States.
  • Shultz DB; Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Canada.
  • Bush K; Department of Radiation Oncology, Stanford University School of Medicine, United States.
  • Trakul N; Department of Radiation Oncology, University of Southern California School of Medicine, United States.
  • Le QT; Department of Radiation Oncology, Stanford University School of Medicine, United States; Stanford Cancer Institute, Stanford University School of Medicine, United States.
  • Diehn M; Department of Radiation Oncology, Stanford University School of Medicine, United States; Stanford Cancer Institute, Stanford University School of Medicine, United States; Institute for Stem Cell Biology & Regenerative Medicine, Stanford University School of Medicine, United States. Electronic ad
  • Loo BW; Department of Radiation Oncology, Stanford University School of Medicine, United States; Stanford Cancer Institute, Stanford University School of Medicine, United States. Electronic address: BWLoo@stanford.edu.
  • Guo HH; Department of Radiology and Nuclear Medicine, Stanford University School of Medicine, United States. Electronic address: henryguo@stanford.edu.
Radiother Oncol ; 119(3): 454-60, 2016 06.
Article en En | MEDLINE | ID: mdl-27267049
PURPOSE: To determine if pre-treatment non-target lung FDG-PET uptake predicts for symptomatic radiation pneumonitis (RP) following lung stereotactic ablative radiotherapy (SABR). METHODS: We reviewed a 258 patient database from our institution to identify 28 patients who experienced symptomatic (grade â©¾ 2) RP after SABR, and compared them to 57 controls who did not develop symptomatic RP. We compared clinical, dosimetric and functional imaging characteristics between the 2 cohorts including pre-treatment non-target lung FDG-PET uptake. RESULTS: Median follow-up time was 26.9 months. Patients who experienced symptomatic RP had significantly higher non-target lung FDG-PET uptake as measured by mean SUV (p < 0.0001) than controls. ROC analysis for symptomatic RP revealed area under the curve (AUC) of 0.74, with sensitivity 82.1% and specificity 57.9% with cutoff mean non-target lung SUV > 0.56. Predictive value increased (AUC of 0.82) when mean non-target lung SUV was combined with mean lung dose (MLD). We developed a 0-2 point model using these 2 variables, 1 point each for SUV > 0.56 or MLD > 5.88 Gy equivalent dose in 2 Gy per fraction (EQD2), predictive for symptomatic RP in our cohort with hazard ratio 10.01 for score 2 versus 0 (p < 0.001). CONCLUSIONS: Patients with elevated pre-SABR non-target lung FDG-PET uptake are at increased risk of symptomatic RP after lung SABR. Our predictive model suggests patients with mean non-target lung SUV > 0.56 and MLD > 5.88 Gy EQD2 are at highest risk. Our predictive model should be validated in an external cohort before clinical implementation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neumonitis por Radiación / Tomografía de Emisión de Positrones / Pulmón / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Radiother Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neumonitis por Radiación / Tomografía de Emisión de Positrones / Pulmón / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Radiother Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Irlanda